Objectives: The efficacy of dapagliflozin as add-on therapy to metformin has been assessed in randomized trials. However, its effectiveness has not been assessed in a US real-world setting. Methods: ...

PHILADELPHIA, PA—Dapagliflozin (Farxiga; AstraZeneca), originally developed for the treatment of type 2 diabetes, has a broad, positive impact across various subsets of patients with chronic heart ...

Data from the DAPA-HF trial and published literature show intermediate-level cost-effectiveness of dapagliflozin use among patients with heart failure with reduced ejection fraction (HFrEF).

Please provide your email address to receive an email when new articles are posted on . Dapagliflozin for worsening HF was both safe and efficacious regardless of diuretic use or dose, according to ...

PHILADELPHIA, PA—Dapagliflozin added to optimal medical therapy results in meaningful improvements in symptoms and health-related quality of life in heart failure patients with reduced ejection ...

Diabetes Drug Cuts Cardiovascular Event Risk in High-Risk Patients Latest findings are from a post hoc meta-analysis of pooled data from the DAPA-HF and DELIVER trials. Dapagliflozin reduces the risk ...

Please provide your email address to receive an email when new articles are posted on . Dapagliflozin was safe and effective at 1 year among older patients with aortic stenosis and HF who underwent ...

Dapagliflozin improved eGFR slope in patients with CKD associated with ADPKD, but it resulted in an increase in kidney volume. Dapagliflozin may exert a protective effect on kidney function in ...

pills Latest findings are from a post hoc meta-analysis of pooled data from the DAPA-HF and DELIVER trials. Dapagliflozin reduces the risk of adverse cardiovascular outcomes outcomes in patients with ...